These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3154530)

  • 1. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluphenazine decanoate and tardive dyskinesia: a possible association.
    Csernansky JG; Grabowski K; Cervantes J; Kaplan J; Yesavage JA
    Am J Psychiatry; 1981 Oct; 138(10):1362-5. PubMed ID: 7294195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluphenazine decanoate and tardive dyskinesia.
    Schiff AA
    Am J Psychiatry; 1982 Jul; 139(7):969-70. PubMed ID: 6124136
    [No Abstract]   [Full Text] [Related]  

  • 5. Tardive dyskinesia, fluphenazine decanoate, and haloperidol.
    Waddington JL
    Am J Psychiatry; 1982 May; 139(5):703-4. PubMed ID: 7072867
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia and depot fluphenazine.
    Nasrallah HA
    Br J Psychiatry; 1979 May; 134():550. PubMed ID: 476364
    [No Abstract]   [Full Text] [Related]  

  • 9. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
    Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
    J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal involuntary movements in patients on long-acting neuroleptics.
    Oyewumi LK; Lapierre YD; Gray R; Batth S; Gelfand R
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):719-23. PubMed ID: 6141614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia and serum iron indices.
    Wirshing DA; Bartzokis G; Pierre JM; Wirshing WC; Sun A; Tishler TA; Marder SR
    Biol Psychiatry; 1998 Sep; 44(6):493-8. PubMed ID: 9777182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentration of depot neuroleptics in tardive dyskinesia.
    Fairbairn AF; Rowell FJ; Hui SM; Hassanyeh F; Robinson AJ; Eccleston D
    Br J Psychiatry; 1983 Jun; 142():579-83. PubMed ID: 6882980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia in schizophrenics under 60 years of age.
    Kolakowska T; Williams AO; Ardern M; Reveley MA
    Biol Psychiatry; 1986 Feb; 21(2):161-9. PubMed ID: 2868762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
    Domino EF
    Psychopharmacology Suppl; 1985; 2():217-23. PubMed ID: 2860660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of tardive dyskinesia in fluphenazine-treated patients.
    Yassa R; Iskandar H; Ally J
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):17S-20S. PubMed ID: 3220966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased incidence of dyskinesias and other behavioral effects of re-exposure to neuroleptic treatment in social colonies of Cebus apella monkeys.
    Linn GS; Lifshitz K; O'Keeffe RT; Lee K; Camp-Lifshitz J
    Psychopharmacology (Berl); 2001 Jan; 153(3):285-94. PubMed ID: 11271400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie R; Mackie M; Morrison D; Kidd J
    Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.